Dopamine receptor D3 deficiency results in chronic depression and anxiety

Behavioural Brain Research

Volumn 274, Issue , 2014, Pages 186-193

  Moraga Amaro, Rodrigo ^a   Gonzalez, Hugo ^b   Pacheco, Rodrigo ^b,c   Stehberg, Jimmy ^a  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b Fundacion Ciencia para la Vida   (Chile)

^c UNIVERSIDAD SAN SEBASTIÁN   (Chile)

Author keywords

Anxiety; Behavior; Depression; Dopamine receptor D3; Knockout mice; Locomotor function

Indexed keywords

DOPAMINE; DOPAMINE 3 RECEPTOR; SUCROSE;

ADULT; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; DARK AND LIGHT EXPLORATION TEST; DEPRESSION; DISEASE ASSOCIATION; FORCED SWIM TEST; IMMOBILITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NEUROPSYCHOLOGICAL TEST; NON MOTOR DEPENDENT SUCROSE TEST; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; SYMPTOM; TAIL SUSPENSION TEST; ANIMAL; C57BL MOUSE; DARK ADAPTATION; DEFICIENCY; DISEASE MODEL; EXPLORATORY BEHAVIOR; FOOD PREFERENCE; GENETICS; IMMOBILIZATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; REACTION TIME; SWIMMING; TONIC IMMOBILITY;

ANIMALS; ANXIETY; CHRONIC DISEASE; DARK ADAPTATION; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FOOD PREFERENCES; HINDLIMB SUSPENSION; IMMOBILITY RESPONSE, TONIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REACTION TIME; RECEPTORS, DOPAMINE D3; SUCROSE; SWIMMING;

EID: 84906770126     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.07.055     Document Type: Article

References (77)

1. Jackson D.M., Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 1994, 64:291-370.
2. Jaber M., Robinson S.W., Missale C., Caron M.G. Dopamine receptors and brain function. Neuropharmacology 1996, 35:1503-1519.
3. Sibley D.R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 1999, 39:313-341.
4. Grandy D.K., Zhang Y.A., Bouvier C., Zhou Q.Y., Johnson R.A., Allen L., et al. Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci USA 1991, 88:9175-9179.
5. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993, 6:602-608.
6. Sibley D.R., Monsma F.J., Shen Y. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 1993, 35:391-415.
7. Drago J., Padungchaichot P., Accili D., Fuchs S. Dopamine receptors and dopamine transporter in brain function and addictive behaviors: insights from targeted mouse mutants. Dev Neurosci 1998, 20:188-203.
8. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225.
9. Baik J.H. Dopamine signaling in reward-related behaviors. Front Neural Circuits 2013, 7:152.
10. Muller D.J., Chowdhury N.I., Zai C.C. The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry 2013, 26:144-150.
11. Dunlop B.M.D., Nemeroff C. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327-337.
12. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
13. Tye K.M., Mirzabekov J.J., Warden M.R., Ferenczi E.A., Tsai H.C., Finkelstein J., et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-541.
14. Gainetdinov R.R., Sotnikova T.D., Grekhova T.V., Rayevsky K.S. Effects of a psychostimulant drug sydnocarb on rat brain dopaminergic transmission in vivo. Eur J Pharmacol 1997, 340:53-58.
15. Jin L., Wu F., Li X., Li H., Du C., Jiang Q., et al. Anti-depressant effects of aqueous extract from acanthopanax senticosus in mice. Phytother Res 2013, 27(12):1829-1833.
16. Skolnick P., Popik P., Janowsky A., Beer B., Lippa A.S. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003, 461:99-104.
17. Skolnick P., Krieter P., Tizzano J., Basile A., Popik P., Czobor P., et al. Preclinical and clinical pharmacology of DOV 216,303, a triple reuptake inhibitor. CNS Drug Rev 2006, 12:123-134.
18. Barone P., Scarzella L., Marconi R., Antonini A., Morgante L., Bracco F., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease A national multicenter parallel-group randomized study. J Neurol 2006, 253:601-607.
19. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P.R., et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002, 4:307-314.
20. Meyer J., Goulding V.S., Wilson A.A., Hussey D., Christensen B.K., Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 2002, 163:102-105.
21. Favier M., Duran T., Carcenac C., Drui G., Savasta M., Carnicella S. Pramipexole reverses Parkinson's disease-related motivational deficits in rats. Mov Disord 2014, 29(7):912-920.
22. Perona M.T., Waters S., Hall F.S., Sora I., Lesch K.P., Murphy D.L., et al. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 2008, 19:566-574.
23. Santiago R.M., Barbiero J., Gradowski R.W., Bochen S., Lima M.M., Da Cunha C., et al. Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin. Behav Brain Res 2014, 259:70-77.
24. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
25. Xing B., Liu P., Jiang W.H., Liu F., Zhang H., Cao G.F., et al. Effects of immobilization stress on emotional behaviors in dopamine D3 receptor knockout mice. Behav Brain Res 2013, 243:261-266.
26. Diaz J., Levesque D., Griffon N., Lammers C.H., Martres M.P., Sokoloff P., et al. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci 1994, 6:1384-1387.
27. Diaz J., Levesque D., Lammers C.H., Griffon N., Martres M.P., Schwartz J.C., et al. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 1995, 65:731-745.
28. Joseph J.D., Wang Y.M., Miles P.R., Budygin E.A., Picetti R., Gainetdinov R.R., et al. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 2002, 112:39-49.
29. Basso A.M., Gallagher K.B., Bratcher N.A., Brioni J.D., Moreland R.B., Hsieh G.C., et al. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 2005, 30:1257-1268.
30. Breuer M.E., Groenink L., Oosting R.S., Buerger E., Korte M., Ferger B., et al. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol 2009, 616:134-140.
31. Chernoloz O., El Mansari M., Blier P. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J Psychiatry Neurosci 2012, 37:113-121.
32. Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28:156-165.
33. Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther 2013, 30:102-113.
34. Lehto S.M., Kuikka J., Tolmunen T., Hintikka J., Viinamaki H., Vanninen R., et al. Temporal cortex dopamine D2/3 receptor binding in major depression. Psychiatry Clin Neurosci 2008, 62:345-348.
35. Ainsworth K., Smith S.E., Zetterstrom T.S., Pei Q., Franklin M., Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl) 1998, 140:470-477.
36. Lammers C., Diaz J., Schwartz J.C., Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000, 5:378-388.
37. Crawley J.N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 1981, 15:695-699.
38. Mathis C., Neumann P.E., Gershenfeld H., Paul S.M., Crawley J.N. Genetic analysis of anxiety-related behaviors and responses to benzodiazepine-related drugs in AXB and BXA recombinant inbred mouse strains. Behav Genet 1995, 25:557-568.
39. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29:547-569.
40. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
41. Castagne V., Moser P., Roux S., Porsolt R.D. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci 2011, 1-8. Chapter 8: Unit 8 10A.
42. Papp M., Willner P., Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 1991, 104:255-259.
43. El Yacoubi M., Bouali S., Popa D., Naudon L., Leroux-Nicollet I., Hamon M., et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci USA 2003, 100:6227-6232.
44. Porsolt R.D., Bertin A., Jalfre M. Behavioural despair in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 1978, 51:291-294.
45. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
46. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.
47. Bolanos C.A., Willey M.D., Maffeo M.L., Powers K.D., Kinka D.W., Grausam K.B., et al. Antidepressant treatment can normalize adult behavioral deficits induced by early-life exposure to methylphenidate. Biol Psychiatry 2008, 63:309-316.
48. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996, 93:1945-1949.
49. Xu M., Koeltzow T.E., Santiago G.T., Moratalla R., Cooper D.C., Hu X.T., et al. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997, 19:837-848.
50. Jung M.Y., Skryabin B.V., Arai M., Abbondanzo S., Fu D., Brosius J., et al. Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors. Neuroscience 1999, 91:911-924.
51. Chourbaji S., Brandwein C., Vogt M.A., Dormann C., Mueller R., Drescher K.U., et al. Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour. Pharmacol Res 2008, 58:302-307.
52. Dailly E., Chenu F., Renard C.E., Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004, 18:601-607.
53. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006, 67(Suppl. 6):3-8.
54. Duncan J., Johnson S., Ou X.M. Monoamine oxidases in major depressive disorder and alcoholism. Drug Discov Ther 2012, 6:112-122.
55. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004, 101:5099-5104.
56. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007, 27:881-885.
57. Li X., Jope R.S. Is glycogen synthase kinase-3 a central modulator in mood regulation. Neuropsychopharmacology 2010, 35:2143-2154.
58. de Bartolomeis A., Avvisati L., Iasevoli F., Tomasetti C. Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment. Eur J Pharmacol 2013, 718:502-523.
59. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010, 167:388-396.
60. Leggio G.M., Salomone S., Bucolo C., Platania C., Micale V., Caraci F., et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013, 719:25-33.
61. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013, 9:193-206.
62. Berman R.M., Fava M., Thase M.E., Trivedi M.H., Swanink R., McQuade R.D., et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009, 14:197-206.
63. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68:843-853.
64. Leentjens A.F., Koester J., Fruh B., Shephard D.T., Barone P., Houben J.J. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009, 31:89-98.
65. Leggio G.M., Micale V., Drago F. Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur Neuropsychopharmacol 2008, 18:271-277.
66. Leggio G.M., Micale V., Le Foll B., Mazzola C., Nobrega J.N., Drago F. Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam. Eur Neuropsychopharmacol 2011, 21:325-332.
67. Contet C., Rawlins J.N., Deacon R.M. A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice. Behav Brain Res 2001, 124:33-46.
68. Newman A.H., Blaylock B.L., Nader M.A., Bergman J., Sibley D.R., Skolnick P. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 2012, 84:882-890.
69. Fleurence R., Williamson R., Jing Y., Kim E., Tran Q.V., Pikalov A.S., et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009, 42:57-90.
70. Stahl S.M. Stahl's essential psychopharmacology neuroscientific basis and practical applications, New York 2008.
71. Savitz J., Hodgkinson C.A., Martin-Soelch C., Shen P.H., Szczepanik J., Nugent A., et al. The functional DRD3 Ser9Gly polymorphism (rs6280) is pleiotropic, affecting reward as well as movement. PLoS One 2013, 8:e54108.
72. Tsuchimine S., Yasui-Furukori N., Nakagami T., Sato Y., Kaneko S. DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study. J Clin Psychopharmacol 2012, 32:724-726.
73. Perlis R.H., Adams D.H., Fijal B., Sutton V.K., Farmen M., Breier A., et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry 2010, 71:599-605.
74. Luippold G., Pech B., Schneider S., Drescher K., Muller R., Gross G., et al. Absence of amino acid-induced glomerular hyperfiltration in dopamine D3 receptor knockout mice. Naunyn Schmiedebergs Arch Pharmacol 2006, 372:284-290.
75. Steiner H., Fuchs S., Accili D. D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav 1997, 63:137-141.
76. Li T., Hou Y., Yan C.X., Chen T., Zhao Y., Li S.B. Dopamine D3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration. Neurosci Lett 2010, 485:256-260.
77. Boulay D., Depoortere R., Rostene W., Perrault G., Sanger D.J. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology 1999, 38:555-565.